Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML.

J Clin Oncol. 2007 Jul 1;25(19):2755-63. Erratum in: J Clin Oncol. 2007 Aug 20;25(24):3790.

PMID:
17602081
2.

Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.

Hensley ML.

Curr Opin Oncol. 2010 Jul;22(4):356-61. doi: 10.1097/CCO.0b013e32833aafef. Review.

PMID:
20520541
3.

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S.

Lancet Oncol. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4.

4.

Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.

Lee EM, Rha SY, Lee J, Park KH, Ahn JH.

Cancer Chemother Pharmacol. 2012 Mar;69(3):635-42. doi: 10.1007/s00280-011-1742-5. Epub 2011 Sep 30.

PMID:
21959979
5.

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.

Dileo P, Morgan JA, Zahrieh D, Desai J, Salesi JM, Harmon DC, Quigley MT, Polson K, Demetri GD, George S.

Cancer. 2007 May 1;109(9):1863-9.

6.

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.

Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K, Baker LH.

J Clin Oncol. 2004 May 1;22(9):1706-12.

PMID:
15117993
7.

Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.

O'Shaughnessy JA, Pluenneke R, Sternberg J, Khandelwal P, Ilegbodu D, Asmar L.

Clin Breast Cancer. 2006 Feb;6(6):505-10.

PMID:
16595033
8.

Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.

Jacobs AD, Otero H, Picozzi VJ Jr, Aboulafia DM.

Cancer Invest. 2004;22(4):505-14.

PMID:
15565807
9.

[Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].

Yao Z, Yang S, Zhao Y, Yao S, Guo H, Liu Y.

Zhonghua Zhong Liu Za Zhi. 2014 Jul;36(7):541-5. Chinese.

PMID:
25327662
10.

Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.

Binder D, Schweisfurth H, Grah C, Schäper C, Temmesfeld-Wollbrück B, Siebert G, Suttorp N, Beinert T.

Cancer Chemother Pharmacol. 2007 Jun;60(1):143-50. Epub 2006 Oct 10.

PMID:
17031643
11.

Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.

Rebattu P, Quantin X, Ardiet C, Morere JF, Azarian MR, Schuller-Lebeau MP, Pujol JL.

Lung Cancer. 2001 Aug-Sep;33(2-3):277-87.

PMID:
11551423
12.

Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.

Späth-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K.

Anticancer Drugs. 2000 Jun;11(5):325-9.

PMID:
10912948
13.

Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

García-Del-Muro X, López-Pousa A, Maurel J, Martín J, Martínez-Trufero J, Casado A, Gómez-España A, Fra J, Cruz J, Poveda A, Meana A, Pericay C, Cubedo R, Rubió J, De Juan A, Laínez N, Carrasco JA, de Andrés R, Buesa JM; Spanish Group for Research on Sarcomas.

J Clin Oncol. 2011 Jun 20;29(18):2528-33. doi: 10.1200/JCO.2010.33.6107. Epub 2011 May 23.

PMID:
21606430
14.

[Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment].

Bay JO, Cabrespine A, Gilliot O, Bailly C, Vincent C, Mishellany F, Gimbergues P.

Bull Cancer. 2007;94 Spec No Actualites:S122-6. Review. French.

PMID:
17845981
15.

Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.

Mora J, Cruz CO, Parareda A, de Torres C.

J Pediatr Hematol Oncol. 2009 Oct;31(10):723-9. doi: 10.1097/MPH.0b013e3181b2598c.

PMID:
19727011
16.

Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.

Nielsen DL, Bjerre KD, Jakobsen EH, Cold S, Stenbygaard L, Sørensen PG, Kamby C, Møller S, Jørgensen CL, Andersson M.

J Clin Oncol. 2011 Dec 20;29(36):4748-54. doi: 10.1200/JCO.2010.33.9507. Epub 2011 Nov 14.

PMID:
22084374
17.

Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.

Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mitry E, Husseini F, Reichardt P, El-Serafi M, Etienne PL, Lingenfelser T, Praet M, Genicot B, Debois M, Nordlinger B, Ducreux MP; European Organisation for Research and Treatment of Cancer Gastrointestinal Group.

J Clin Oncol. 2005 Dec 20;23(36):9250-6.

PMID:
16361622
18.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.

J Clin Oncol. 2006 Aug 20;24(24):3946-52.

PMID:
16921047
19.

Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.

Niho S, Kubota K, Goto K, Ohmatsu H, Matsumoto T, Kakinuma R, Nishiwaki Y.

Cancer Chemother Pharmacol. 2003 Jul;52(1):19-24. Epub 2003 Apr 24.

PMID:
12712259
20.

A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.

Davis EJ, Chugh R, Zhao L, Lucas DR, Biermann JS, Zalupski MM, Feng M, Wong SL, Jacobson J, Zyczynski L, Reinke D, Metko G, Baker LH, Schuetze SM.

Eur J Cancer. 2015 Sep;51(13):1794-802. doi: 10.1016/j.ejca.2015.05.010. Epub 2015 Jun 9.

PMID:
26066736

Supplemental Content

Support Center